AR054259A1 - Vacuna contra virus de papiloma humano (hpv) - Google Patents

Vacuna contra virus de papiloma humano (hpv)

Info

Publication number
AR054259A1
AR054259A1 AR20060101619A ARP060101619A AR054259A1 AR 054259 A1 AR054259 A1 AR 054259A1 AR 20060101619 A AR20060101619 A AR 20060101619A AR P060101619 A ARP060101619 A AR P060101619A AR 054259 A1 AR054259 A1 AR 054259A1
Authority
AR
Argentina
Prior art keywords
hpv
protein
vaccine
immunogenic fragment
against human
Prior art date
Application number
AR20060101619A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054259(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0509010A external-priority patent/GB0509010D0/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR054259A1 publication Critical patent/AR054259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procedimiento para la prevencion de infeccion y/o enfermedad por HPV, comprendiendo el procedimiento suministrar una primera vacuna contra HPV que comprende una proteína L1 o fragmento inmunogénico de la misma de al menos HPV 16 y HPV18, y una segunda vacuna contra HPV que no comprende los componentes L1 de HPV 16 y HPV 18 de la primera vacuna, y que comprende la segunda vacuna una proteína L1 o fragmento inmunogénico de la misma de al menos un tipo de HPV oncogénico diferente, done la primera y segunda vacunas pueden suministrarse en cualquier orden y el suministro está separado por un intervalo de tiempo adecuado. Reivindicacion 1: Uso de una proteína L1 de virus de papiloma humano o fragmento inmunogénico de la misma de un primer tipo de HPV en la preparacion de un medicamento para reforzar una respuesta inmune previamente provocada por una proteína L1 de virus de papiloma humano o fragmento inmunogénico dela misma de un tipo de HPV diferente. Reivindicacion 20: Una composicion de vacuna que comprende una combinacion de una proteína L1 de HPV 31 o fragmento inmunogénico de la misma y una proteína L1 de HPV 45 o un fragmento inmunogénico de la misma, no conteniendo la vacuna proteína L1 de HPV 16 o HPV 18 o fragmentos inmunogénicos de la misma. Reivindicacion 22: Un kit que comprende una primera y segunda composiciones de vacuna de acuerdo con la reivindicacion 11.
AR20060101619A 2005-04-26 2006-04-24 Vacuna contra virus de papiloma humano (hpv) AR054259A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67482905P 2005-04-26 2005-04-26
GB0509010A GB0509010D0 (en) 2005-05-03 2005-05-03 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (1)

Publication Number Publication Date
AR054259A1 true AR054259A1 (es) 2007-06-13

Family

ID=36992675

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101619A AR054259A1 (es) 2005-04-26 2006-04-24 Vacuna contra virus de papiloma humano (hpv)

Country Status (12)

Country Link
US (1) US20090181052A1 (es)
EP (1) EP1877086A2 (es)
JP (1) JP2008539184A (es)
KR (1) KR20080005585A (es)
AR (1) AR054259A1 (es)
AU (1) AU2006239422A1 (es)
CA (1) CA2606092A1 (es)
EA (1) EA013326B1 (es)
MX (1) MX2007013472A (es)
NO (1) NO20075194L (es)
SG (1) SG159525A1 (es)
WO (1) WO2006114312A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP6022159B2 (ja) * 2008-07-31 2016-11-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗ｈｐｖワクチン
WO2010147268A1 (ko) * 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2510457C (en) * 2002-12-20 2011-12-06 Glaxosmithkline Biologicals S.A. Hpv-16 and -18 l1 vlp vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
NO20075194L (no) 2008-01-18
CA2606092A1 (en) 2006-11-02
KR20080005585A (ko) 2008-01-14
SG159525A1 (en) 2010-03-30
WO2006114312A3 (en) 2007-04-05
AU2006239422A1 (en) 2006-11-02
EA013326B1 (ru) 2010-04-30
EA200702079A1 (ru) 2008-04-28
EP1877086A2 (en) 2008-01-16
WO2006114312A2 (en) 2006-11-02
MX2007013472A (es) 2008-04-02
US20090181052A1 (en) 2009-07-16
JP2008539184A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
AR040204A1 (es) Composicion de vacuna meningococica multivalente
ECSP045300A (es) Antígenos virales
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
AR055603A1 (es) Vacuna contra la infeccion por virus del dengue
MY169275A (en) Method of immunization against the four serotypes of dengue
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
ECSP055869A (es) Vacuna hpv-16 y -18 l1 vlp
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
AR071741A1 (es) Vacunas contra la malaria
HRP20100473T1 (hr) Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
BR112022015313A2 (pt) Vacina de hpv
BRPI0516314A (pt) uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
CO6341567A2 (es) Vacuna contra el virus de papiloma humano
AR049354A1 (es) VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal